title: Prognostic significance of p53 and p21(waf1/cip1) immunoreactivity in epithelial cancers of the ovary.
abstract: OBJECTIVE
  Theprognostic value of p53 expression in epithelial ovarian cancer remains unresolved. We hypothesized that prognosis may relate more to expression of p21(waf1/cip1), the major downstream effector of p53, which can also be induced through p53-independent mechanisms. We therefore studied the relationship of p53 and p21(waf1/cip1) expression in epithelial ovarian cancers to clinicopathological variables and prognosis.
  
  
  METHODS
  Fixed, embedded tumors from 85 patients with untreated, primary epithelial ovarian cancer were immunostained with antibodies to p53 and p21(waf1/cip1). Expression was correlated with clinicopathological features and prognosis. Survival curves were calculated by the Kaplan-Meier method and compared using the log-rank test for p53, p21(waf1/cip1), and all combinations of expression of the two markers.
  
  
  RESULTS
  Sixty-two percent of tumors expressed p53, and 42% expressed p21(waf1/cip1). There was no correlation between p53 and p21(waf1/cip1) expression. Advanced stage, grade, age >/=50, and p53 expression were associated with worse disease-free survival. Patients whose tumors were p53(+)/waf1(-), however, had a particularly strong association with poorer disease-free survival when compared with other combinations of p53 and p21(waf1/cip1) expression (P = 0.003). Neither p53, nor p21(waf1/cip1), nor combinations of expression were independently related to survival when histology, age, stage, and differentiation were considered.
  
  
  CONCLUSIONS
  p53 expression in the absence of p21(waf1/cip1) expression is a better marker of poor prognosis than either p53 or p21(waf1/cip1) expression status alone in univariate analysis. Absence of independent prognostic significance may be related to the paucity of early stage cases in the current study.
authors.affiliation: Division of Pathology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
authors.forename: B A
authors.initials: BA
authors.lastname: Werness
authors.forename: A N
authors.initials: AN
authors.lastname: Freedman
authors.forename: M S
authors.initials: MS
authors.lastname: Piver
authors.forename: M
authors.initials: M
authors.lastname: Romero-Gutierrez
authors.forename: E
authors.initials: E
authors.lastname: Petrow
mesh_terms: D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D009364:Neoplasm Recurrence, Local / Q000737:chemistry; D009375:Neoplasms, Glandular and Epithelial / Q000737:chemistry* / Q000401:mortality; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000401:mortality; D010053:Ovary / Q000737:chemistry; D011379:Prognosis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
chemical_list: C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D016159:Tumor Suppressor Protein p53